Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A confirmatory trial of Ibritumomab-tiuxetan

Trial Profile

A confirmatory trial of Ibritumomab-tiuxetan

Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 15 Sep 2017 New trial record
    • 07 Sep 2017 According to a CASI Pharmaceuticals media release, the confirmatory trial is required as part of the registration process for the import drug registration.
    • 07 Sep 2017 According to a CASI Pharmaceuticals media release, the CFDA review of the import drug clinical trial application (CTA) for Ibritumomab-tiuxetan is in process. The ZEVALIN antibody kit and the radioactive Yttrium-90 component of the clinical trial application require separate submissions to the CFDA, which the first part is currently under review and the latter part is in the submission process. The company expects to initiate the confirmatory trial within six months after CTA approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top